Document is current

Article History

Received: 29 August 2022

Accepted: 14 December 2022

First Online: 18 February 2023

Competing interests

: Blessie Elizabeth Nelson, Jason Roszik, and Naifa Lamki Busaidy report no disclosures. Filip Janku reports grants from Agios, Asana, Astellas, Bicara, BioMed Valley Discoveries, Bristol Myers Squibb, Fujifilm, Genentech, Novartis, Plexxikon, PIQUR Therapeutics, Proximagen, Symphogen, and Synthorx; grants and other support from Deciphera, IDEAYA, and SOTIO; other support from Guardant Health, IFM, Illumina, PureTech Health, and Synlogic; personal fees and other support from Cardiff Oncology; and personal fees from Immunomet outside the submitted work. Shumei Kato serves as a consultant for Foundation Medicine, NeoGenomics and CureMatch. He receives a speaker’s fee from Roche and is on the Pfizer advisory board. He has research funding from ACT Genomics, Sysmex, Konica Minolta, and OmniSeq. Aung Naing reports research funding from NCI, EMD Serono, MedImmune, Healios Oncology Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, BMS, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, Arcus Biosciences, NeoimmuneTech, ImmuneOncia, and Surface Oncology. Dr. Naing is on the advisory board of CytomX Therapeutics, Novartis and Genome & Company, OncoSec KEYNOTE-695, STCube, Takeda, CSL, Behring, Horizon, and Pharming. Travel and accommodation expenses have been received from ARMO BioSciences. Spouse research funding was received from the Immune Deficiency Foundation, the Jeffery Modell Foundation, the Chao Physician-Scientist Award, and Baxalta. David S. Hong reports research/grant funding from AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP), Novartis, Pfizer, Seattle Genetics, Takeda, and Turning Point Therapeutics. Travel accommodation, and expense support has been received from Bayer, Genmab, the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), POET, CCLO, and the Society for Immunotherapy of Cancer (SITC). He has served in a consulting or advisory role for Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity, Liberium, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza, Therapeutics, and WebMD. He has other ownership interests in Molecular Match (advisor), OncoResponse (founder), and Presagia Inc. (advisor). Sarina A. Piha-Paul receives research/grant funding from AbbVie, Inc., ABM Therapeutics, Inc., Acepodia, Inc., Alkermes, Aminex Therapeutics, Amphivena Therapeutics, Inc., BioMarin Pharmaceutical, Inc., Boehringer Ingelheim, Bristol Myers Squib, Cerulean Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Curis, Inc., Daiichi Sankyo, Eli Lilly, ENB Therapeutics, Five Prime Therapeutics, Gene Quantum, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd., Medimmune, LLC., Medivation, Inc., Merck Sharp and Dohme Corp., Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer; Principia Biopharma, Inc., Puma Biotechnology, Inc., Rapt Therapeutics, Inc., Seattle Genetics, Silverback Therapeutics, Taiho Oncology, Tesaro, Inc., and TransThera Bio. Siqing Fu reports research funding from AstraZeneca, Abbisko, Anaeropharma Science, Arrien Pharmaceuticals, BeiGene, BioAtla, LLC, Boehringer Ingelheim, Eli Lilly & Co., Hookipa Biotech, Huya Bioscience International, IMV, Inc., Innovent Biologics, Co., Ltd., Lyvgen Biopharm, Co., Ltd., MacroGenics, Medivir AB, Millennium Pharmaceuticals, Inc., Nerviano Medical Sciences, NeuPharma, inc., Novartis, OncoMed Pharmaceuticals, Parexel International, LLC, Sellas Life Sciences Group, Soricimed Biopharma, Inc., Tolero Pharmaceuticals, NovoCure, Turnstone Biologics, Taiho Oncology, and Abbisko. Apostolia-Maria Tsimberidou has received research funding from Immatics, the Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, and Tvardi Therapeutics and has a consulting or advisory role for Covance, Genentech, and Tempus. Maria Cabanillas reports funding from Merck and Genentech and is on the consulting and advisory boards for Bayer, Lilly, Exelixis, and Blueprint. Milind Javle reports research funding from QED, Novartis, and Meclun. He has received honoraria from Taiho, Seattle Genetics, and Merck; and has served as a consultant for Origimed, More Health, EDO, Incyte, Taiho, EMD Serono, and Oncosil. His institution has received research funding from Arqule and Lilly. John K. Heymach receives research support from OneOme and is a consultant for Quest Diagnostics and 23andMe. He has served on an advisory committee for Novartis and has provided educational content for the American College of Clinical Pharmacy, Florida Pharmacy Association and HorizonCME. F. Meric-Bernstam reports receiving grants from Calithera Biosciences and Novartis, receives personal fees from AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks, Black Diamond, Biovica, Eisai, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis; and grants from Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Curis Inc., Cytomx Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Puma Biotechnology Inc., and Taiho Pharmaceutical Co. Vivek Subbiah reports grants from Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals; and Helsinn Pharmaceuticals. He also reports grants and services in an advisory board/consultant position for Eli Lilly/Loxo Oncology. He has received research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, the University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune and has served on an advisory board and/or as a consultant for Helsinn, Incyte, QED Pharma, Daiichi Sankyo, Signant Health, Novartis, Relay therapeutics, Roche, and Medimmune. He has received travel funds from Pharmamar, Incyte, ASCO, and ESMO and has received other support from Medscape.